# A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Source: https://onco.cc/trials/nct06616766/  
OnCo record `nct06616766` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of YH42946 in non-small-cell lung cancer, run by Yuhan Corporation, now recruiting.

## Summary

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 is a phase 1/2 interventional study registered as NCT06616766 by Yuhan Corporation, with 201 participants planned, started 2024-10-02 and due to reach its primary completion in 2028-03-15. Interventions recorded: YH42946.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06616766
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion
- Sponsor: Yuhan Corporation
- Enrolled: 201

## Sources

- ClinicalTrials.gov NCT06616766: https://clinicaltrials.gov/study/NCT06616766

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06616766.json